CRIS Current Research Information System

DE GIGLIO, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.106
NA - Nord America 1.451
EU - Europa 1.251
SA - Sud America 162
AF - Africa 113
OC - Oceania 2
Totale 6.085
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.413
SG - Singapore 888
CN - Cina 831
VN - Vietnam 656
IT - Italia 507
HK - Hong Kong 309
NL - Olanda 182
IN - India 142
KR - Corea 139
BR - Brasile 123
DE - Germania 116
SE - Svezia 92
IE - Irlanda 66
FI - Finlandia 59
GB - Regno Unito 49
JO - Giordania 48
CI - Costa d'Avorio 43
RU - Federazione Russa 33
CH - Svizzera 32
JP - Giappone 31
ID - Indonesia 27
FR - Francia 26
TG - Togo 26
BG - Bulgaria 23
CA - Canada 19
AR - Argentina 17
AT - Austria 17
MX - Messico 15
SC - Seychelles 15
ES - Italia 12
NG - Nigeria 12
PL - Polonia 9
IQ - Iraq 8
BE - Belgio 6
ZA - Sudafrica 6
BD - Bangladesh 5
CO - Colombia 5
EC - Ecuador 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
KE - Kenya 4
LT - Lituania 4
UA - Ucraina 4
GR - Grecia 3
PK - Pakistan 3
PY - Paraguay 3
VE - Venezuela 3
AU - Australia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
DK - Danimarca 2
EG - Egitto 2
IL - Israele 2
LU - Lussemburgo 2
MY - Malesia 2
TR - Turchia 2
UZ - Uzbekistan 2
AL - Albania 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
GM - Gambi 1
IS - Islanda 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
NI - Nicaragua 1
PE - Perù 1
PH - Filippine 1
SR - Suriname 1
SV - El Salvador 1
TN - Tunisia 1
TW - Taiwan 1
Totale 6.085
Salva come PNG Salva come JPEG
Città #
Singapore 572
Hefei 314
Hong Kong 305
Ashburn 298
Ho Chi Minh City 197
Santa Clara 197
Hanoi 152
Seoul 138
Beijing 129
Dallas 103
Boardman 84
Bologna 84
Dublin 66
Hyderabad 66
Chandler 59
Milan 57
Amman 48
Los Angeles 46
Abidjan 43
Seattle 41
Dong Ket 30
Munich 30
Bengaluru 28
Helsinki 27
Redondo Beach 27
Lomé 26
Tokyo 24
Bern 23
Sofia 23
Cinquefrondi 22
New York 21
Turin 21
Fairfield 20
Buffalo 19
Ha Long 19
Haiphong 19
Jakarta 19
Princeton 19
Turku 18
Rome 17
Southend 17
Visakhapatnam 17
Da Nang 16
Nuremberg 16
Quận Bình Thạnh 16
Woodbridge 16
Biên Hòa 15
Frankfurt am Main 15
Messina 15
Modena 14
Ninh Bình 14
Shanghai 14
Guangzhou 13
Houston 13
Bắc Ninh 12
Falkenstein 12
Lappeenranta 12
Bắc Giang 11
São Paulo 11
Abeokuta 10
Cambridge 10
Redmond 10
Vienna 10
Wilmington 10
Amsterdam 9
Quận Một 9
Tongling 9
Chicago 8
Hải Dương 8
Stockholm 8
Tianjin 8
Cesena 7
Chongqing 7
London 7
Moncalieri 7
Phoenix 7
Poplar 7
San Diego 7
Vinh 7
Warsaw 7
Brussels 6
Can Tho 6
Council Bluffs 6
Elk Grove Village 6
Lizzano 6
Mexico City 6
Quận Phú Nhuận 6
Thái Nguyên 6
Toronto 6
Berlin 5
Denver 5
Florence 5
Montreal 5
Orem 5
Quảng Ninh 5
Rancho Palos Verdes 5
Ravenna 5
Rio de Janeiro 5
Thái Bình 5
Verona 5
Totale 4.001
Salva come PNG Salva come JPEG
Nome #
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 239
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 192
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report 182
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 173
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 157
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) 153
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 147
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 139
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 138
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 138
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience 135
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 131
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 127
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 126
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 120
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 118
Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond 117
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) 113
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks 112
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 108
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 103
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives 102
Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients 101
Immunobiology of thymic epithelial tumors: Implications for immunotherapy with immune checkpoint inhibitors 101
Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer 99
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 91
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis 90
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis 89
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? 88
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians 88
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach 85
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances 83
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis 79
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib 76
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 74
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy 73
Histopathological Evidence for a Non-Inflammatory Mechanism in Osimertinib-Induced Myopathy: A Case Report 72
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 69
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials 65
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 63
Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review 62
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities 60
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study 59
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database 57
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 54
Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici) 54
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 54
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: Rationale, evidence and place in therapy 52
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 51
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 50
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome 48
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) 48
Carboplatin, nab-paclitaxel plus atezolizumab in Impower 130 trial: New weapons beyond controversies 47
IMpower 132: Is the Second Exception to the Rule No Longer an Exception? 47
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience 46
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation 46
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 45
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 45
Primary angiosarcoma of the kidney: Case report and comprehensive literature review 43
Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis 42
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 42
Antibody–drug conjugates for lung cancer in the era of personalized oncology 41
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics 41
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 40
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 40
Ductal breast carcinoma metastatic to the stomach resembling primary linitis plastica in a male patient 39
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non–small-cell Lung Cancer Progressing on Crizotinib 39
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: The Italian expanded access program 38
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 36
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 34
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis 34
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) 34
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 33
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)) 33
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort 33
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 32
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 32
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer 30
Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression 29
Totale 6.246
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202199 0 0 0 0 0 22 1 5 7 2 3 59
2021/2022174 3 2 1 4 8 6 0 37 20 10 53 30
2022/2023575 26 40 19 27 77 46 12 49 162 37 28 52
2023/2024395 36 47 26 25 23 73 9 62 16 25 39 14
2024/20252.140 113 137 131 135 302 113 214 74 55 217 172 477
2025/20262.829 638 794 419 418 361 199 0 0 0 0 0 0
Totale 6.246